SUPN (Supernus Pharmaceuticals, Inc.) Stock Financials & Earnings

SUPNSupernus Pharmaceuticals, Inc.

Mkt Cap$3B

Revenue (TTM)$719M

Net Income (TTM)-$39M

EPS (TTM)-$0.68

Free Cash Flow (TTM)$73M

Gross Margin85.5%

Op. Margin-6.2%

Net Margin-5.4%

FCF Margin10.1%

P/S Ratio (TTM)4.5x

P/E Ratio (TTM)—

YoY Rev Growth+8.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$154M	$130M	$5M
Q2 23	$136M	$114M	-$18M
Q3 23	$154M	$134M	$8M
Q4 23	$164M	$145M	-$996K
Q1 24	$144M	$127M	-$3M
Q2 24	$168M	$150M	$23M
Q3 24	$176M	$158M	$41M
Q4 24	$174M	$148M	$21M
Q1 25	$150M	$134M	-$10M
Q2 25	$165M	$149M	$12M
Q3 25	$192M	$144M	-$60M
Q4 25	$212M	$189M	$14M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$21M	$28M	$57M	—
Q2 23	$24M	$27M	$60M	—
Q3 23	$23M	$26M	$57M	—
Q4 23	$23M	$26M	$55M	—
Q1 24	$25M	$27M	$60M	—
Q2 24	$26M	$27M	$59M	—
Q3 24	$29M	$15M	$54M	—
Q4 24	$29M	$25M	$55M	—
Q1 25	$27M	$27M	$63M	—
Q2 25	$22M	$28M	$65M	—
Q3 25	$29M	—	—	$180M
Q4 25	$28M	—	—	$122M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$58M	$170M	$229M
Q2 23	$25M	$127M	$152M
Q3 23	$95M	$105M	$200M
Q4 23	$75M	$180M	$255M
Q1 24	$63M	$234M	$298M
Q2 24	$52M	$295M	$347M
Q3 24	$32M	$372M	$403M
Q4 24	$69M	$384M	$454M
Q1 25	$116M	$348M	$464M
Q2 25	$145M	$378M	$523M
Q3 25	$151M	$130M	$281M
Q4 25	$128.4B	$180.2B	$308.7B

Shares Outstanding

Revenue Per Employee

Revenue / Employee